Author: terra7520873378

Topelia Australia, a biotech company established to commercialise a novel ATT treatment for Australians in quarantine, has launched an investment program designed to keep the invention Australian owned – while rolling out treatment to the world. Prof Thomas Borody – Topelia announces US$25 mil Series A capital raise to fund manufacture and clinical trials of the COVID-19 Antiviral Triple Therapy (ATT).– Topelia has secured exclusive global patent rights to COVID-19 Antiviral Triple Therapy from Prof Thomas Borody.– Borody’s track record includes effective treatment for Peptic Ulcers & Crohn’s Disease, recolonisation of bowel microbiome, and 3 FDA approved drugs on the ... Read more